Biocon arm inks pact to launch biosimilar Bmab 1200 in multiple countries

The biopharmaceutical company said that its subsidiary, Biocon Biologics has secured market entry for its proposed biosimilar, Bmab 1200, which is designed to compete with Stelara, in Europe, the UK, Canada, and Japan.